Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
- Authors:
- Fuming Zi
- Huapu Zi
- Yi Li
- Jingsong He
- Qingzhi Shi
- Zhen Cai
-
Affiliations: Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330008, P.R. China, Department of Oncology, Rizhao Traditional Chinese Medicine Hospital of Shandong Traditional Chinese Medicine University, Rizhao, Shandong 276800, P.R. China, Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China - Published online on: November 14, 2017 https://doi.org/10.3892/ol.2017.7412
- Pages: 683-690
-
Copyright: © Zi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Marble A: Diabetes and cancer. N Engl J Med. 211:339–349. 1934. View Article : Google Scholar | |
Simon D: I.15 Diabetes and cancer. Diabetes Res Clin Pract. 103:S52014. View Article : Google Scholar | |
Pandey A, Forte V, Abdallah M, Alickaj A, Mahmud S, Asad S and McFarlane SI: Diabetes mellitus and the risk of cancer. Minerva Endocrinol. 36:187–209. 2011.PubMed/NCBI | |
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI | |
Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 21:433–440. 2003. View Article : Google Scholar : PubMed/NCBI | |
Coughlin SS, Calle EE, Teras LR, Petrelli J and Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 159:1160–1167. 2004. View Article : Google Scholar : PubMed/NCBI | |
Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC and Brancati FL: Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA. 300:2754–2764. 2008. View Article : Google Scholar : PubMed/NCBI | |
Rao Kondapally, Seshasai S, Kaptoge S, Thompson A, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, et al: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 364:829–841. 2011. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Ji J, Sundquist K, Sundquist J and Hemminki K: The impact of type 2 diabetes mellitus on cancer-specific survival: A follow-up study in Sweden. Cancer. 118:1353–1361. 2012. View Article : Google Scholar : PubMed/NCBI | |
Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL: Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI | |
Vigneri P, Frasca F, Sciacca L, Pandini G and Vigneri R: Diabetes and cancer. Endocr Relat Cancer. 16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake is associated with better survival in ovarian cancer: A case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar : PubMed/NCBI | |
Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E and Schwab M: Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 34:126–135. 2013. View Article : Google Scholar : PubMed/NCBI | |
Rizos CV and Elisaf MS: Metformin and cancer. Eur J Pharmacol. 705:96–108. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bost F, Sahra IB, Le Marchand-Brustel Y and Tanti JF: Metformin and cancer therapy. Curr Opin Oncol. 24:103–108. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yang YX, Hennessy S and Lewis JD: Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol. 3:587–594. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lee MY, Lin KD, Hsiao PJ and Shin SJ: The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism. 61:242–249. 2012. View Article : Google Scholar : PubMed/NCBI | |
Goodwin P: Meta-analysis: Diabetes appears to increase risk, mortality of breast and colon cancers. Oncol Times. 35:332013. View Article : Google Scholar | |
Kasper JS and Giovannucci E: A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 15:2056–2062. 2006. View Article : Google Scholar : PubMed/NCBI | |
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM and Kristal AR: Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 15:1977–1983. 2006. View Article : Google Scholar : PubMed/NCBI | |
Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, et al: History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control. 18:493–503. 2007. View Article : Google Scholar : PubMed/NCBI | |
Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, et al: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 39:977–983. 2007. View Article : Google Scholar : PubMed/NCBI | |
Frayling TM, Colhoun H and Florez JC: A genetic link between type 2 diabetes and prostate cancer. Diabetologia. 51:1757–1760. 2008. View Article : Google Scholar : PubMed/NCBI | |
Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, Patel AV, Berndt SI, Albanes D and Hayes RB: HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate. 70:601–607. 2010. View Article : Google Scholar : PubMed/NCBI | |
Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN and Haiman CA: Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 169:937–945. 2009. View Article : Google Scholar : PubMed/NCBI | |
Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, Derr RL, Wolff AC, Carducci MA and Brancati FL: Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 13:58–64. 2010. View Article : Google Scholar : PubMed/NCBI | |
Issa ZA, Zantout MS and Azar ST: Multiple myeloma and diabetes. ISRN Endocrinol. 2011:8150132011. View Article : Google Scholar : PubMed/NCBI | |
Castillo JJ, Mull N, Reagan JL, Nemr S and Mitri J: Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: A meta-analysis of observational studies. Blood. 119:4845–4850. 2012. View Article : Google Scholar : PubMed/NCBI | |
Noto H, Tsujimoto T, Sasazuki T and Noda M: Significantly increased risk of cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Endocr Pract. 17:616–628. 2011. View Article : Google Scholar : PubMed/NCBI | |
El-Serag HB, Hampel H and Javadi F: The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 4:369–380. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G and Wang L: Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies. Int J Cancer. 130:1639–1648. 2012. View Article : Google Scholar : PubMed/NCBI | |
Friberg E, Orsini N, Mantzoros CS and Wolk A: Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 50:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI | |
Larsson SC, Orsini N and Wolk A: Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst. 97:1679–1687. 2005. View Article : Google Scholar : PubMed/NCBI | |
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F and Woodward M: Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer. 92:2076–2083. 2005. View Article : Google Scholar : PubMed/NCBI | |
Everhart J and Wright D: Diabetes mellitus as a risk factor for pancreatic cancer: A meta-analysis. JAMA. 273:1605–1609. 1995. View Article : Google Scholar : PubMed/NCBI | |
Larsson SC, Mantzoros CS and Wolk A: Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer. 121:856–862. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wolf I, Sadetzki S, Catane R, Karasik A and Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol. 6:103–111. 2005. View Article : Google Scholar : PubMed/NCBI | |
Bonovas S, Filioussi K and Tsantes A: Diabetes mellitus and risk of prostate cancer: A meta-analysis. Diabetologia. 47:1071–1078. 2004. View Article : Google Scholar : PubMed/NCBI | |
Larsson SC, Orsini N, Brismar K and Wolk A: Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia. 49:2819–2823. 2006. View Article : Google Scholar : PubMed/NCBI | |
Chao C and Page JH: Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: A systematic review and meta-analysis. Am J Epidemiol. 168:471–480. 2008. View Article : Google Scholar : PubMed/NCBI | |
Mitri J, Castillo J and Pittas AG: Diabetes and Risk of Non-Hodgkin's Lymphoma A meta-analysis of observational studies. Diabetes Care. 31:2391–2397. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gallagher EJ and LeRoith D: The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chowdhury T: Diabetes and cancer. QJM. 103:905–915. 2010. View Article : Google Scholar : PubMed/NCBI | |
Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y and Seke Etet PF: Insulin resistance and cancer: The role of insulin and IGFs. Endocr Relat Cancer. 20:R1–R17. 2013. View Article : Google Scholar : PubMed/NCBI | |
Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA: Metformin: Multi-faceted protection against cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI | |
Clayton PE, Banerjee I, Murray PG and Renehan AG: Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 7:11–24. 2011. View Article : Google Scholar : PubMed/NCBI | |
Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012.PubMed/NCBI | |
Cohen DH and LeRoith D: Obesity, type 2 diabetes, and cancer: The insulin and IGF connection. Endocr Relat Cancer. 19:F27–F45. 2012. View Article : Google Scholar : PubMed/NCBI | |
Donath MY and Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 11:98–107. 2011. View Article : Google Scholar : PubMed/NCBI | |
Xie W and Du L: Diabetes is an inflammatory disease: Evidence from traditional Chinese medicines. Diabetes Obes Metab. 13:289–301. 2011. View Article : Google Scholar : PubMed/NCBI | |
Cosentino F and Assenza GE: Diabetes and Inflammation. Herz. 29:749–759. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kern PA, Ranganathan S, Li C, Wood L and Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 280:E745–751. 2001.PubMed/NCBI | |
Neurath MF and Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 22:83–89. 2011. View Article : Google Scholar : PubMed/NCBI | |
Waters JP, Pober JS and Bradley JR: Tumour necrosis factor and cancer. J Pathol. 230:241–248. 2013. View Article : Google Scholar : PubMed/NCBI | |
Geerlings SE and Hoepelman AI: Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 26:259–265. 1999. View Article : Google Scholar : PubMed/NCBI | |
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI | |
Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI | |
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI | |
Li D, Yeung SC, Hassan MM, Konopleva M and Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 137:482–488. 2009. View Article : Google Scholar : PubMed/NCBI | |
Currie CJ, Poole CD and Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 52:1766–1777. 2009. View Article : Google Scholar : PubMed/NCBI | |
Donadon V, Balbi M, Valent F and Avogaro A: Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol. 16:3025–3032. 2010. View Article : Google Scholar : PubMed/NCBI | |
Donadon V, Balbi M, Mas MD, Casarin P and Zanette G: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 30:750–758. 2010. View Article : Google Scholar : PubMed/NCBI | |
Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 33:322–326. 2010. View Article : Google Scholar : PubMed/NCBI | |
Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI | |
Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bodmer M, Meier C, Krähenbühl S, Jick SS and Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 33:1304–1308. 2010. View Article : Google Scholar : PubMed/NCBI | |
Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, Burman KD, Wartofsky L and Vasko V: Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 98:3269–3279. 2013. View Article : Google Scholar : PubMed/NCBI | |
Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012. View Article : Google Scholar : PubMed/NCBI | |
Patel T, Hruby G, Badani K, Abate-Shen C and McKiernan JM: Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology. 76:1240–1244. 2010. View Article : Google Scholar : PubMed/NCBI | |
Azoulay L, Dell'Aniello S, Gagnon B, Pollak M and Suissa S: Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev. 20:337–344. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wright JL and Stanford JL: Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control. 20:1617–1622. 2009. View Article : Google Scholar : PubMed/NCBI | |
He XX, Tu SM, Lee MH and Yeung SC: Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 22:2640–2645. 2011. View Article : Google Scholar : PubMed/NCBI | |
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M and Li D: Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI | |
Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One. 7:e334112012. View Article : Google Scholar : PubMed/NCBI | |
Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al: Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 3:1077–1083. 2010. View Article : Google Scholar : PubMed/NCBI | |
Freemark M and Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 107:E552001. View Article : Google Scholar : PubMed/NCBI | |
Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008. View Article : Google Scholar : PubMed/NCBI | |
Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M and Fantus IG: Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 8:501–505. 2008. View Article : Google Scholar : PubMed/NCBI | |
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD and Dennis PA: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). 3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI | |
Algire C, Amrein L, Bazile M, David S, Zakikhani M and Pollak M: Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 30:1174–1182. 2011. View Article : Google Scholar : PubMed/NCBI | |
Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI | |
Karnevi E, Said K, Andersson R and Rosendahl AH: Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 13:2352013. View Article : Google Scholar : PubMed/NCBI | |
Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI | |
Inoki K, Zhu T and Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI | |
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI | |
Efeyan A and Sabatini DM: mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol. 22:169–176. 2010. View Article : Google Scholar : PubMed/NCBI | |
Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zakikhani M, Dowling RJ, Sonenberg N and Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 1:369–375. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI | |
Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI | |
Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, et al: The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 116:4262–4273. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M, et al: Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 19:5372–5380. 2013. View Article : Google Scholar : PubMed/NCBI | |
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y and Zhao WL: Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 3:e2752012. View Article : Google Scholar : PubMed/NCBI | |
Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:4366–4372. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI | |
Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M and Gotlieb WH: Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, et al: Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett. 356:443–453. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liang J and Mills GB: AMPK: A contextual oncogene or tumor suppressor? Cancer Res. 73:2929–2935. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hardie DG: The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell. 23:131–132. 2013. View Article : Google Scholar : PubMed/NCBI | |
Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al: AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 8:733–741. 2009. View Article : Google Scholar : PubMed/NCBI | |
Baumann P, Mandl-Weber S, Emmerich B, Straka C and Schmidmaier R: Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs. 18:405–410. 2007. View Article : Google Scholar : PubMed/NCBI | |
Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS and Shaw RJ: LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 23:143–158. 2013. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, et al: Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci USA. 111:pp. E435–E444. 2014; View Article : Google Scholar : PubMed/NCBI | |
Garcia A and Tisman G: Metformin, B(12), and enhanced breast cancer response to chemotherapy. J Clin Oncol. 28:e19–e20. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, et al: Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70:2465–2475. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ben Sahra I, Tanti JF and Bost F: The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy. 6:670–671. 2010. View Article : Google Scholar | |
Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH and Venkateswaran V: Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 15:346–352. 2012. View Article : Google Scholar : PubMed/NCBI | |
Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI | |
Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA and Bae-Jump VL: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 125:458–469. 2012. View Article : Google Scholar : PubMed/NCBI | |
Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V and Harhaji-Trajkovic L: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50. 2011. View Article : Google Scholar : PubMed/NCBI | |
Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI | |
Eyler CE and Rich JN: Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 26:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI | |
Clevers H: The cancer stem cell: Premises, promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B and Menendez JA: Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 3:395–398. 2012. View Article : Google Scholar : PubMed/NCBI | |
Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI | |
Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S and Sarkar FH: Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 5:355–364. 2012. View Article : Google Scholar : PubMed/NCBI | |
Mayer MJ, Klotz LH and Venkateswaran V: Metformin and prostate cancer stem cells: A novel therapeutic target. Prostate Cancer Prostatic Dis. 18:303–309. 2015. View Article : Google Scholar : PubMed/NCBI | |
Di Francesco AM, Toesca A, Cenciarelli C, Giordano A, Gasbarrini A and Puglisi MA: Metabolic modification in gastrointestinal cancer stem cells: Characteristics and therapeutic approaches. J Cell Physiol. 231:2081–2087. 2016. View Article : Google Scholar : PubMed/NCBI | |
Florio T: Antitumoral effects of metformin on cancer stem cells. Ann d'Endocrinologie. 76:2962015. View Article : Google Scholar | |
Rattan R, Ali Fehmi R and Munkarah A: Metformin: An emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI | |
Bednar F and Simeone DM: Metformin and cancer stem cells: Old drug, new targets. Cancer Prev Res (Phila). 5:351–354. 2012. View Article : Google Scholar : PubMed/NCBI |